A seamless blend of advanced science and market strategy is Bioxytran, Inc. brings to the table. Their firm standing in the OTC market, a robust market cap of $24.5M+, and a focused approach to Glycovirology and Hypoxia is setting them up as a force to be reckoned with in the biopharmaceutical industry.